Aida Pharmaceuticals, one of mainland China's leading pharmaceutical companies, has announced that it was granted an additional patent related to its Rh-Apo2L anti-cancer drug, the second of three patents that had been applied for which Aida believes places it at the vanguard of China's pharmaceutical industry.
The patent was jointly granted by China's State Intellectual Property Office to East China University of Science& Technology and Aida's majority-controlled subsidiary, Shanghai Quiaer Biotechnology Company, Ltd. ECUST is the partner with Aida in the research of this field.
Mr Jinsong Zhou, the CEO of Shanghai Qiaer stated, "This continues to establish Aida as a technology leader in not only the Chinese pharmaceutical field, but also in the international arena. Our scientists and researchers are deeply encouraged by the news and will reinforce our confidence in the ongoing clinical trials of Rh-Apo2L."